Company CEO is featured speaker: "Case Study - Screening Ion Channels for
Safety and Efficacy" on Friday, September 26 at 11:30
CLEVELAND, Sept. 18 /PRNewswire/ -- ChanTest will feature its expanding line of ion channel services and cell lines for drug-discovery and development applications in booth 11 at the Assays and Cellular Targets conference in San Diego, September 24-26. ChanTest designed its ion channel cell lines and services to provide drug-discovery researchers the early information they need to identify the most promising target compounds and eliminate those that could ultimately cause harmful side effects. ChanTest is also working with pharmaceutical and biotech companies to help rescue shelved pharmaceutical compounds.
Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will present a case study to conference participants entitled, "Screening Ion Channels for Safety and Efficacy," on Friday, September 26 at 11:30, as part of the conference's Ion Channel Targets track. "We are developing a library of ion channel-expressing cell lines for screening with the full range of automated patch clamp instruments and FLIPR-Tetra(r)," said Dr. Brown. "At present, 86 'books' are available and 160 will be available by June 2009. We validate each cell line for cDNA sequence, Western blot, voltage range, gating, and pharmacology. We recognize that each research program has its own unique needs and priorities, so we've designed our services and cell lines to offer the most flexibility possible. Our validated ion channels can be mixed and matched into panels according to tissue, e.g., cardiac; therapeutic area, e.g., pain; and ion channel family, e.g., TRP channels. And we draw upon our years of ion channel experience to help customers design an appropriate testing program to meet their specific scientific and budgetary goals."
ChanTest scientists were the first to prove hERG as the target for
adverse cardiac events linked to non-c
Copyright©2008 PR Newswire.
All rights reserved